SecBot SecBot

MDGL

MADRIGAL PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001157601 Biotech & Drug Discovery
$423.96 −3.43 (−0.80%)
Nov 16 4:00 PM ET · prev $427.39
Market cap
$9.9B
Mid cap
Consensus
Buy
92% Buy or better · 26 analysts
Median target
$660.00
+56% · range $479.00–962.00
1 year
−23.4%
from $553.42 · Nov 17
30 days
−5.2%
from $447.09
52-week range
$396.32–602.83
−30% from high · low Nov 3
Avg volume 20D
594.1K
Nov 4 spike 2.31M
Short interest
2.14M
≈9.2% of shares · −2.6%
Days to cover
7.6
at average volume
Insider net
+$26.6M
1 buyer · 2 sellers · since Jun 17
New fund stakes
3
Q2 2026 13F · 1 exit
Filing reports
16
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 5 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $35.0M at an average $381.49. 2 insiders sold $8.4M. Price is 11% above their cost.

  • InstitutionsMIXED

    Q2 2026: 36 added (3 new), 32 trimmed or exited. Largest new: Holocene Advisors $82.1M, Hrt Financial $45.4M.

  • AnalystsBULLISH

    24 of 26 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −2.6% to 2.14M shares. 7.6 days to cover, ≈9.2% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 22.

Who's buying

13F· Q2 2026
3
new positions
1
exit
$170.0M
in new stakes
FundMoveSharesValue
UBS Group AGDOUBLED401,708$215.7M
FMR LLCTRIM356,201$191.3M
AMERIPRISE FINANCIAL INCDOUBLED231,205$124.1M
JANE STREET GROUP, LLCDOUBLED191,541$102.8M
PRICE T ROWE ASSOCIATES INC /MD/TRIM187,226$100.5M
ALLIANCEBERNSTEIN L.P.ADD189,458$99.2M
TORONTO DOMINION BANKADD181,432$97.4M
Hood River Capital Management LLCTRIM169,084$90.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

26 analysts
Buy 92% rate it Buy or better
Strong Buy7Buy17Hold2Sell0Strong Sell0
12-month targets · 18 analysts

Price is below the lowest target. Median implies +56%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 4, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 4, 2026Truist Securities
REITERATE
REITERATEBuy
Nov 3, 2026Citigroup
MAINTAIN
MAINTAINBuy
Sep 23, 2026Citigroup
INITIATE
INITIATEBuy
Aug 4, 2026Wolfe Research
UPGRADE
UPGRADEOutperform
Aug 3, 2026Barclays
MAINTAIN
MAINTAINOverweight

Washington

Corporate Lobbying

27 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$35.0M
bought · 1 insider
$8.4M
sold · 2 insiders
+11.1%
vs their $381.49 cost
DateInsiderTypeValue
Nov 6, 2026
Kelley Shannon T
General Counsel
Nov 6, 2026
SELL$430.8K
Nov 6, 2026
BAKER BROS. ADVISORS LP
Director
Nov 6, 2026
BUY$793.2K
Nov 6, 2026
BAKER BROS. ADVISORS LP
Director
Nov 6, 2026
BUY$23.1M
Nov 6, 2026
BAKER BROS. ADVISORS LP
Director
Nov 6, 2026
BUY$5.3M
Nov 4, 2026
BAKER BROS. ADVISORS LP
Director
Nov 4, 2026
BUY$3.7M
Nov 4, 2026
BAKER BROS. ADVISORS LP
Director
Nov 4, 2026
BUY$2.1M
Sep 11, 2026
Sibold William John
President and CEO
Sep 11, 2026
SELL$32.0K
Sep 11, 2026
Sibold William John
President and CEO
Sep 11, 2026
SELL$116.8K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY-$2.00-$2.00–-$2.00+69.2%$1.6B
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
2,136,404
shares short
-2.6%
vs prior settlement
7.6
days to cover
≈9.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 Other
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) t
Nov 6, 2026 SEC
Analysis based on filing metadata only; document content was unavailable. This is an amendment to a Schedule 13D for…
SC 13D/A · Impact 3/10
Nov 6, 2026 SEC
Baker Bros. Advisors, a director and top institutional holder, made a $2.05M open-market purchase of MDGL on Nov 4…
INSIDER-BUY · Impact 5/10
Nov 6, 2026 Insider
Kelley Shannon T sold 1,077 shares
General Counsel @ $400.00 ($430.8K)
Nov 6, 2026 Insider
BAKER BROS. ADVISORS LP bought 2,000 shares
Director @ $396.61 ($793.2K)
Nov 6, 2026 Insider
BAKER BROS. ADVISORS LP bought 60,400 shares
Director @ $383.02 ($23.1M)
Nov 5, 2026 Press
Madrigal presented multiple real-world studies at AASLD showing Rezdiffra patients achieve consistent improvements in…
Impact 5/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 13, 2026
Press release
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate…
Nov 11, 2026
Press release
Investigation of MDGL Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, Pa., Nov. 11, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law…
Nov 11, 2026
Combo signal
Combo Signal: MDGL · 3 insider buys + SC 13D/A filing
3 insider purchases in 7 days combined with activist filing (SC 13D/A) in 14 days.
Nov 11, 2026
Press release
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into…
Nov 6, 2026
Press release
Notice of Investigation of MDGL: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, Pa., Nov. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm…

SecBot reports

16 filings · 2 press releases · 6 bullish · 0 bearish · 1 mixed · 9 neutral
All MDGL filing & press-release reports (18)